Table 2.

Inflammatory protein expression in the skin of healthy control subjects and HS patients

	Protein	NN (n = 10)	HS (n = 20)	Unadjusted P value
	pg/mg skin tissue	Median (IQR) or x/total	Median (IQR) or x/total	Unadjusted P value
1	IL‐16	10.90 (7.67‐13.09)	57.54 (38.50‐120.81)	<0.001^a
2	IL‐17A	0/10	15/20	<0.001^a
3	CXCL‐8 (IL‐8)	0.30 (0.21‐1.30)	5.90 (1.25‐19.48)	0.001^a
4	IL‐12/23p40	0.10 (0.08‐0.17)	0.25 (0.14‐0.47)	0.007^a
5	CCL‐4 (MIP‐1β)	0.13 (0.08‐0.15)	0.62 (0.19‐1.83)	0.011^a
6	CXCL‐10 (IP‐10)	0.66 (0.18‐1.10)	1.80 (1.07‐3.32)	0.011^a
7	IL‐8 HA	0/10	10/20	0.011^a
8	TNF‐β	1/10	9/20	0.101
9	CCL‐3 (MIP‐1α)	2/10	11/20	0.119
10	INF‐γ	3/10	13/20	0.122
11	TNF‐α	0/10	5/20	0.140
12	IL‐1β	0.13 (0.07‐0.18)	0.21 (0.08‐0.73)	0.155
13	CCL‐13 (MCP‐4)	0.66 (0.53‐0.72)	0.36 (0.25‐0.66)	0.172
14	IL‐10	0.009 (0.005‐0.011)	0.006 (0.004‐0.008)	0.183
15	CCL‐17 (TARC)	2/10	9/20	0.246
16	IL‐5	0.024 (0.019‐0.039)	0.017 (0.013‐0.029)	0.322
17	IL‐1α	1.28 (0.92‐2.10)	1.54 (0.86‐4.40)	0.350
18	IL‐2	0.035 (0.016‐0.081)	0.031 (0.023‐0.039)	0.530
19	IL‐6	0.26 (0.02‐0.41)	0.08 (0.03‐0.54)	0.530
20	CCL‐2 (MCP‐1)	3.13 (0.30‐4.82)	1.43 (0.42‐3.35)	0.588
21	IL‐15	0.029 (0.026‐0.039)	0.035 (0.026‐0.045)	0.588
22	CCL‐11 (Eotaxin‐1)	4/10	11/20	0.700
23	CCL‐22 (MDC)	1.80 (1.44‐3.44)	1.82 (1.23‐3.25)	0.983
24	IL‐13	0/10	1/20	1.000
25	IL‐12p70	3/10	6/20	1.000
26	CCL‐26 (Eotaxin‐3)	ND	ND	‐
27	IL‐7	NA	NA	‐
28	VEGF	NA	NA	‐
29	IL‐4	NA	NA	‐
30	GM‐CSF	NA	NA	‐

IL‐8 HA (human antibody) has been validated for the MSD V‐PLEX™ kit and is recommended when high CXCL/IL‐8 levels are anticipated.

HS, hidradenitis suppurativa patients; IQR, interquartile range; LLOQ, lowest level of quantification; NA, not analyzed, not validated for skin samples; ND, not detected; NN, healthy controls; x, number of samples with a detectable value.

Significant after correction with the Benjamini‐Hochberg test (P < 0.014).